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Abstract 
Background: The present study investigated whether prochlorperazine affects 
vestibular-ocular reflex (VOR) and vestibulo-perceptual function. Methods: We 
studied 12 healthy naïve subjects 3 hours after a single dose of oral prochlorperazine 
5mg in a randomised, placebo-controlled, double-blind, cross-over study in healthy 
young subjects. Two rotational tests in yaw were used: 1) a Threshold task 
investigating perceptual motion detection and nystagmic thresholds (acceleration 
steps of 0.5deg/s/s) and 2) Suprathreshold responses to velocity steps of 90deg/s in 
which vestibulo-ocular (VO) and vestibulo-perceptual (VP) time constants of decay, 
as well as VOR gain, were measured. Results: Prochlorperazine had no effect upon 
any measure of nystagmic or perceptual vestibular function compared to placebo. This 
lack of effects on vestibular-mediated motion perception suggests that the drug is 
likely to act more as an antiemetic than as an anti-vertiginous agent.  
 
Introduction 
Acute vestibular disorders induce severe vertigo usually associated with nausea and 
vomiting. Relief of these symptoms is the first task for the clinician. In many 
countries including the United Kingdom, prochlorperazine is perhaps the drug most 
commonly prescribed in the acute scenario [Patka et al., 2011] and the British 
National Formulary (“BNF”) lists its indications as “severe nausea, vomiting, vertigo, 
labyrinthine disorders [JointFormularyCommittee, 2012]. Prochlorperazine 
suppresses vomiting by modulating messages from the vestibular system to the 
vomiting centres at the chemo-receptor trigger zone (CTZ) [Yang and Neff, 1974] yet 
any anti-vertiginous effect is unproven. 
 The hypothesis of the study was that oral prochlorperazine modulates 
vestibular-motion (ocular reflex and perceptual) signals. This is important to try to 
establish if the drug beneficial effects is due to action on the vestibular system per se 
i.e. truly anti-vertiginous. If prochlorperazine has no effect on vestibular parameters 
one would have to conclude that the mechanism of action of the drug is only anti-
emetic. Significant suppression of vestibular responses by prochlorperazine (our 
primary outcome) would also impact the reliability of clinical testing in acute 
vestibular patients taking the drug. As many vertiginous patients included in clinical 
research projects are under the effects of this drug, the findings in our study may 
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clarify if some of the vestibulo-ocular and vestibulo-perceptual abnormalities detected 
acutely in patients may be due to the effects of the drug rather than the vestibular 
lesion itself. In particular, vestibulo-perceptual time constants are particularly 
shortened in acute vestibular neuritis patients and it was suggested that this 
represented a cortical ‘shut down’ with a net anti-vertiginous effect [Cousins et al., 
2013]. However, the possibility that this perceptual effect was drug induced was not 
directly investigated. We now address these questions as a double-blind, randomised, 
cross-over, placebo controlled, non-clinical drug trial on healthy subjects.  
 
Methods 
12 healthy naïve, right-handed subjects (aged 19-34 years, mean 22.7 years, 6 
females), verified by clinical history, participated and gave signed consent. The study 
was approved by the local ethics committee. The number of subjects included was 
based on previous experiments using this vestibular methods in normal subjects, as in 
the current study [Kyriakareli et al., 2013].  
 
Prochlorperazine and Placebo 
The local hospital pharmacy supplied prochlorperazine as the brand “Stemetil” as a 
single 5mg unmarked film-coated tablet in an unremarkable bottle (Stemetil 5mg 
tablets are bioequivalent to prochlorperazine 5mg tablets (MHRA guidelines, 
PL17907/0072)). The Placebo (indistinct lactose) was issued identically. A computer 
generated randomisation list was unknown to the authors. The 5mg dose was chosen 
as it is the BNF [JointFormularyCommittee, 2012] starting oral recommended dose 
(3mg for the buccal preparation). 
 Maximum potency of a 5mg stemetil tablet (Bristol Laboratories Limited, 
UK) is achieved after 3.1 hours (MHRA, PL17907/0072). Testing was performed 3.0 
hours after taking the tablet, at the same time of day for each subject and all were 
asked to avoid caffeine. Testing took approximately 40 minutes and conducted in two 
sessions separated by one week (i.e., cross-over design).  
 
Experimental Protocol 
Subjects sat in a vibration-free Barany Chair (Contravez Inc) with head restrained by 
a chin rest and in complete darkness. White noise was amplified through two speakers 
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fixed to the chair behind the head to mask any surroundings sound clues that may 
indicate rotation.  
Given that the result of the study could be related to drug-induced changes to 
alertness [Nigam et al., 1985], we performed a simple reaction time test immediately 
before rotational testing: pressing a button as fast as possible with the thumb of the 
dominant hand upon hearing a loud beep. Mean reaction time was calculated from 5 
trials.  
 
Vestibular Tests 
Two tests were performed; a vestibular threshold motion detection task and a supra-
threshold task in which vestibulo-ocular and perceptual time constants were 
measured. The order of these tests was randomised. A detailed explanation of the 
measurements and analysis is provided elsewhere [Cutfield et al., 2011; Okada et al., 
1999]. Below summarises the methods in brief: 
 
Vestibular threshold test 
The chair rotated about the yaw plane (i.e., horizontally), increasing in velocity in 
steps of 0.5 deg/s2 every 3 seconds. Subjects were rotated in total ten times, 5 times to 
the left and 5 times to the right in random order. A one minute rest was given between 
each rotation.  
Subjects held a two button box controller with both hands, pressing the left 
button to indicate a perceived leftward rotation and the right button when they 
perceived a rightward rotation. Each subject was given an identical instruction to 
press the right/left button as soon as they felt motion, and to not press any button if 
they had any doubt about motion or direction. The time to button press indicates the 
vestibulo-perceptual threshold (Figure 1A), which can be expressed as either time (s) 
or chair velocity (deg/s).  
Eye movements were simultaneously captured through electro-oculography 
(EOG) sampled at 250 Hz. EOG signals were passed through a low-pass filter (cut-off 
30 Hz) prior to analysis. The nystagmic or vestibulo-ocular threshold i.e., onset time 
of nystagmus, was obtained from the raw eye movement trace and a differentiated and 
de-saccaded eye movement trace (see [Cousins et al., 2013; Okada et al., 1999] for 
further technical details).   
An average perceptual and eye movement onset time was obtained.  
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Suprathreshold vestibular task 
The chair was rapidly accelerated (1s) in the yaw plane to a constant velocity of 90°/s 
using a rotational step stimulus [Okada et al., 1999]. The velocity was constant until 
the nystagmus had stopped and never less than 60s. A total of 4 rotations, two in each 
direction, and four stopping responses were obtained. The direction order was 
randomised.    
Subjects signalled their perceived or subjective angular velocity by turning a 
tachometer wheel with their right hand at the onset of perceived rotation in either 
direction (onset and stopping responses). Instructions were given to subjects to turn 
the wheel as fast as comfortably possible initially on chair acceleration/deceleration 
for the first couple of seconds. From then on they should slow down the wheel turning 
congruently with their perceived angular velocity until they no longer felt rotating, at 
which point they should stop turning the wheel. All subjects turned the wheel in the 
direction of actual motion. An output voltage proportional to the angular velocity of 
the wheel was digitally sampled at 250 Hz. An average waveform was normalised for 
size variations between subjects; accordingly amplitude units are arbitrary and hence 
not considered further herewith.   
Eye movements were simultaneously captured with EOG sampled at 250 Hz 
and passed through a low-pass filter (cut-off 30 Hz) prior to analysis. The EOG 
signals were displayed raw and also differentiated, de-saccaded and visible artefacts 
removed (i.e., blinks). An averaged, calibrated and normalised in amplitude slow 
phase eye movement trace was obtained for each subject.  
Analysis of tachometer-wheel (vestibulo-perceptual) and slow phase eye 
movement (vestibulo-ocular) supra-threshold responses (Figure 1B) was the average 
of the combined 8 accelerations/decelerations as right and left rotations produced 
similar responses. The duration of the differentiated slow phase nystagmic response 
and of the perceptual responses, and the (normalised) Area under Curve was obtained. 
Also, an exponential was fitted to the perceptual and slow phase eye velocity 
movements attaining the time constant of decay of the vestibulo-ocular and vestibulo-
perceptual responses; in this way the ocular and perceptual velocity storage 
mechanisms are assessed [Bertolini et al., 2011; Shaikh et al., 2013]. The time 
constant was derived from the best fit exponential line by visual overlap of a 
computer generated curve and response curve and high correlation coefficient (r) 
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(Figure 1C). This measure is amplitude independent. Gain of the slow phase eye 
movement response (VOR) was calculated, defined as peak eye velocity / peak 
stimulus velocity (90 deg/s). 
 
Statistical Analysis 
Data analysis of responses was performed by two blinded examiners. An unblinded 
statistician compared the responses between examiners and performed all statistics 
(J.G). Mixed ANOVAs with factors: drug, order, examiner were employed as well as 
paired t-tests for specific investigations (reaction time test, examiner effect, direction 
of rotation).  Significance level was set as double tailed p<0.05. 
 
Results 
The two examiners analyses of rotational responses were similar and no interaction 
between examiner and drug effect was found. The mean from the two blinded 
examiners’ analyses was therefore used.  
Blinded participants were unable to distinguish between the two tablets and 
none experienced an adverse response. Oculomotor recordings from one subject 
(Subject 7) were lost.     
Mean reaction time was very similar and not significantly different between 
prochlorperazine (0.25s) and placebo (0.23s).  
 
Vestibulo-ocular and vestibulo-perceptual threshold tasks  
Upon perceiving angular movement, all subjects pressed either the right or left button 
as instructed. On three occasions, different subjects pressed the incorrect button for 
direction and this response was excluded (once on placebo). Nystagmic thresholds 
were attained quicker than perceptual thresholds, as observed in previous research 
[Cousins et al., 2013]. There was no significant difference between leftward and 
rightward rotations. 
As illustrated in figure 2, nystagmic threshold for prochlorperazine was 6.3s 
(S.E.M + 0.24) and placebo 6.7s (S.E.M + 0.2) from the onset of rotation, 
corresponding to a mean chair rotational velocity of 4.9 and 5.7 deg/s respectively. 
Perceptual threshold for prochlorperazine was 10.0s (S.E.M + 1.17) and placebo 
10.23s (S.E.M + 1.18), which correspond to a mean chair rotational velocity of 11.0 
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and 11.8 deg/s respectively. ANOVA showed no drug or order effect for any measure 
of nystagmic or perceptual threshold during the vestibular motion detection task.    
 
Vestibulo-ocular and vestibulo-perceptual supra-threshold task 
During rotation all subjects turned the tachometer wheel in the direction of 
movement, always stopping wheel rotation before 60s. Upon stopping the chairs’ 
rotation, all subjects turned the wheel toward the opposite direction reflecting a 
perceived change in movement direction. There was no significant difference between 
leftward and rightward rotations.  
Shown in figure 3, Nystagmic duration for prochlorperazine was 39.5s (S.E.M 
+ 1.28) and placebo 42.5s (S.E.M + 1.19). Nystagmic time constant for 
prochlorperazine was 13.85s (S.E.M + 0.76) and placebo 14.65s (S.E.M + 0.74). 
Nystagmic area under Curve for prochlorperazine was 51.9 degrees (S.E.M + 15.0) 
and placebo 51.6 degrees (S.E.M + 9.99). VOR gain for prochlorperazine was 0.45 
and placebo 0.52. Perceptual duration of rotation for prochlorperazine was 26.5s 
(S.E.M + 2.81) and placebo 31.43s (S.E.M + 3.27). Perceptual time constant for 
prochlorperazine was 15.02s (S.E.M + 1.64) and placebo 16.62s (S.E.M + 1.92). 
Perceptual area under Curve for prochlorperazine was 70.94 arbitrary units (a.u.) 
(S.E.M + 10.57) and placebo 82.06 a.u. (S.E.M + 11.36). 
 ANOVA showed no drug or order effect on any measure of nystagmus or 
motion perception i.e., there was no difference between prochlorperazine and placebo.   
 
Discussion 
We found no significant effects of prochlorperazine upon any measure of ocular or 
perceptual function.  
 
Vestibular motion detection – threshold task 
The vestibular motion detection technique used has previously shown elevated 
bilateral vestibulo-ocular and vestibulo-perceptual thresholds in acute unilateral 
vestibular neuritis [Cousins et al., 2013; Cutfield et al., 2011]. One pending question 
was whether the anti-vertiginous drugs some of these patients received (usually 
prochlororperazine in the UK) played any role in this bi-directional threshold 
elevation. This would make sense as ideally a vestibular suppressant drug should 
elevate vestibular thresholds, in particular perceptual. The present results attest 
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against this possibility and hence, the bilateral threshold elevation observed in acute 
vestibular neuritis, is likely the result of the reduced signal-to-noise ratio following 
the vestibular loss as postulated by Cousins et al. [Cousins et al., 2013].  
 
Vestibular velocity storage mechanism – suprathreshold task 
The normal prolongation of vestibular-ocular and perceptual time constants to values 
of 13-16s (i.e. double those of the vestibular nerve time constant [Ramat and 
Bertolini, 2009] is due to a central integrator known as ‘velocity storage’ [Raphan et 
al., 1979].  Professional dancers, figure skaters and jet fighter pilots [Cohen et al., 
2003] show reduced vestibular time constants due to a process of vestibular 
habituation thought to involve velocity storage processing. For this reason, we 
expected that any anti-vertiginous or vestibular suppressant effects (as these drugs are 
often referred to) of prochlororperazine would involve the velocity storage 
mechanism, presumably shortening vestibular nystagmic and/or perceptual time 
constants. However, we found no effect of prochlorperazine on the time constants of 
decay of the vestibulo-ocular or vestibulo-perceptual post-rotational responses or the 
gain of the VOR. Contrastingly, baclofen, a GABA-B agonist, reduces the vestibular 
time constant [Dai et al., 2006], whereas promethazine (a drug with antihistaminic 
H1/anticholinergic properties)  has no effect [Cohen et al., 2003].    
 
Prochlorperazine reduces vomiting by inhibiting dopamine (D2) receptors 
(Yang and Neff 1974). As we found no effect of prochlorperazine on vestibular 
function tests, and given that the primary mechanism of action of prochlorperazine is 
as a dopamine antagonist, our results suggest that dopaminergic involvement in the 
vestibular system is small. Indeed, only a small number of dopaminergic neurones can 
be found in the medial vestibular nucleus (MVN) of rats [Cransac et al., 1996].  
 
Study limitations 
Although the current experiment was performed in a young cohort, the responses 
were consistent with those of older adults, age-matched to vestibular neuritis patients 
[Cousins et al., 2013]. In addition, we used healthy subjects as opposed to patients 
who might have a different response to prochlorperazine. However, our past 
investigations show that patients taking prochlorperazine respond within the same 
range to patients who are not on the drug during the same vestibular tests used here 
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[Cousins et al., 2013]. Still, the drug effects in patients would need to be specifically 
studied.     
 
Conclusions 
Whilst oral prochlorperazine is an accepted therapy for vomiting and nausea, it seems 
to have no effect on vestibular motion detection or on the vestibular velocity storage 
mechanism (ocular and perceptual). Therefore it would seem to offer little relief for 
unwanted vestibular-mediated motion feelings (vertigo) in dizzy patients. 
Prochlorperazine is unlikely to affect clinical assessments of vestibular function 
(nystagmic or perceptual) in dizzy patients, but it has to be acknowledged that our 
study was only conducted in normal subjects. The beneficial effects of 
prochlororperazine, and perhaps related drugs, may be due to anti-emetic action.  
Higher doses of this drug may well have an effect on vestibular function but clinical 
experience and pharmacological studies [Nigam et al., 1985] indicate that, at higher 
doses, general CNS effects, alertness and cognitive in particular, would be very 
difficult to disentangle from true central vestibular effects.  
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Figure 1 (A) Example response to a chair rotation and calculations of nystagmic and 
perceptual motion detection from the raw traces (B) Wheel tachometer output and Eye 
movements (VOR) (C) Example fitted exponential curve and time constant for the 
perceptual vestibular time constant (arbitrary units).  
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Figure 2: Mean vestibulo-ocular and vestibulo-perceptual thresholds and SEM for 
Placebo (grey) and Prochlorperazine (striped). There were no significant differences 
between prochlorperazine and placebo. 
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Figure 3: Mean and SEM for duration, time constant, VOR gain and Area under 
Curve from vestibulo-ocular (nystagmic) and vestibulo-perceptual (wheel tachometer) 
responses for Placebo (grey) and Prochlorperazine (striped). There were no significant 
differences between prochlorperazine and placebo.  
 
 
 
 
 
 
 
 
 
 
